SCHEMBL178071

SCHEMBL178071

CN1C[C@H](CO)C=C2c3cccc4[nH]cc(c34)C[C@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 1.00
KDM4E B2RXH2 6/20 1.00
ALDH1A1 P00352 6/20 1.00
MEN1 O00255 6/20 1.00
KMT2A Q03164 6/20 1.00
CYP2D6 P10635 6/20 1.00
MAPT P10636 5/20 1.00
CYP3A4 P08684 4/20 1.00
HPGD P15428 4/20 1.00
HIF1A Q16665 3/20 1.00
USP2 O75604 2/20 1.00
CYP1A2 P05177 2/20 1.00
GAA P10253 1/20 1.00
TAAR1 Q96RJ0 1/20 1.00
RECQL P46063 3/20 0.66
PLEC Q15149 1/20 0.66
DRD3 P35462 7/20 0.64
DRD2 P14416 6/20 0.64
HTR2B P41595 6/20 0.64
HTR6 P50406 6/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14029480 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL30278505 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL10471429 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL25042463 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL7176983 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL25042462 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL9820435 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL25042461 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
SCHEMBL257961 1.00 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1MEN1KMT2A
Methyl Alcohol SCHEMBL27814674 0.99 HSD17B10 (0.98) HSD17B10KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 681 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026043908-A1 COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS ALLTECH, INC. (US) 2026-02-26 WO claimed
EP-4674894-A2 COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES Hemoteq AG (DE) 2026-01-07 EP claimed
EP-4663688-A2 CROSSLINKERS Hemoteq AG (DE) 2025-12-17 EP claimed
EP-4401713-A1 ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS Nulixir Inc. (US) 2024-07-24 EP claimed
EP-4401711-A1 STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME Nulixir Inc. (US) 2024-07-24 EP claimed
EP-4401714-A1 ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME Nulixir Inc. (US) 2024-07-24 EP claimed
US-11964049-B2 Water soluble compositions and methods of making the same Nulixir Inc. (US) 2024-04-23 US claimed
US-20240041792-A1 TOPICAL COMPOSITIONS AND USES THEREOF TRUETIVA, Inc. (US) 2024-02-08 US claimed
WO-2024023715-A1 TOPICAL COMPOSITIONS AND USES THEREOF Truetiva Inc. (US) 2024-02-01 WO claimed
US-20230277477-A1 COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES TRUETIVA, Inc. (US) 2023-09-07 US claimed
EP-0156645-B1 PROCESS FOR THE PREPARATION OF N1-METHYL-10ALPHA-METHOXYLUMILYSERGOL AND ESTERS THEREOF, AND INTERMEDIATES FOR THEIR PREPARATION INVERNI DELLA BEFFA S.P.A. (IT) 1989-11-02 EP claimed
EP-0171988-B1 A PROCESS FOR PREPARING LYSERGOL DERIVATIVES INVERNI DELLA BEFFA S.P.A. (IT) 1989-06-21 EP claimed
EP-0251652-A2 t-Butyl ergoline derivatives FARMITALIA CARLO ERBA S.r.l. (IT) 1988-01-07 EP claimed
EP-0209456-A1 Process for the preparation of N-methyl lysergol RHONE-POULENC SANTE (FR) 1987-01-21 EP claimed
CN-86104086-A The preparation method of 2-halogen nicergoline derivatives and its acid salt and new 2-halogen Varson class 1986-12-17 CN claimed
EP-0171988-A2 A process for preparing lysergol derivatives INVERNI DELLA BEFFA S.P.A. (IT) 1986-02-19 EP claimed
EP-0004664-B1 A PROCESS FOR PREPARING LYSERGOL DERIVATIVES Corvi Mora, Enrico (IT) 1982-04-14 EP claimed
US-4232157-A Process for preparing lysergol derivatives ISTITUTO CHEMIOTERAPICO DI LODI SPA, A CORP OF ITALY (IT) 1980-11-04 US claimed
US-4198344-A Process for the preparation of polyhydroxylated steroids, lysergol and ergolinic alkaloids SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1980-04-15 US claimed
EP-0004664-A1 A process for preparing lysergol derivatives Corvi Mora, Enrico (IT) 1979-10-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277477-A1 COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES CNR2, CNR1, FAAH HSD17B10 1138/4885KDM4E 1425/4885ALDH1A1 3832/4885
US-20240041792-A1 TOPICAL COMPOSITIONS AND USES THEREOF COL14A1, COL2A1, COL1A1 HSD17B10 2780/4885KDM4E 2436/4885ALDH1A1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.